Regulators have authorized an antiviral drug from Merck known as molnupiravir that may help blunt the wave of infections driven by the omicron variant.
the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death bySome experts question whether there will be much of a role for the Merck drug in the U.S.
“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.” For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.
Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
U.S. FDA set to authorize Pfizer, Merck COVID-19 pills this week - Bloomberg NewsThe U.S. Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer Inc and Merck as early as Wednesday, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Baca lebih lajut »
U.S. FDA set to authorize Pfizer, Merck COVID-19 pills this week - Bloomberg NewsThe U.S. Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer Inc and Merck as early as Wednesday, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Baca lebih lajut »
U.S. FDA authorizes Merck's at-home antiviral COVID-19 pillThe U.S. Food and Drug Administration on Thursday authorized Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving the go-ahead to a similar treatment from Pfizer Inc for high-risk patients above the age of 12.
Baca lebih lajut »
FDA authorizes first Covid pill, from Pfizer, for emergency useBREAKING: FDA authorizes first Covid-19 antiviral pill in the US to protect against severe disease.
Baca lebih lajut »
FDA authorizes 1st COVID-19 pill to protect against severe diseaseThe Food and Drug Administration on Wednesday authorized the first COVID-19 antiviral pill in the United States to protect against severe disease.
Baca lebih lajut »
FDA authorizes first pill to treat Covid-19The FDA authorizes the first pill to treat Covid-19. Pfizer's Paxlovid is meant to be taken at home before people are sick enough to be hospitalized.
Baca lebih lajut »